Published in Clin Exp Metastasis on April 04, 2012
Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients. Ann Surg Oncol (2013) 0.81
Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins. Oncotarget (2016) 0.76
A glimpse of the ERM proteins. J Biomed Sci (2016) 0.75
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma. PLoS One (2016) 0.75
Inherent aggressive character of invasive and non-invasive cells dictates the in vitro migration pattern of multicellular spheroid. Sci Rep (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A (1992) 8.69
Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2006) 6.64
How does the extracellular matrix direct gene expression? J Theor Biol (1982) 6.38
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol (2001) 6.21
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development (1989) 5.62
Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol (2010) 5.05
Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci (2003) 3.52
Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci U S A (1994) 3.09
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol (2006) 2.84
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol (2000) 2.39
Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 2.21
Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res (2001) 2.10
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell (2003) 1.67
Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol (2001) 1.61
ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol (2002) 1.61
Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res (1990) 1.53
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res (2004) 1.44
High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun (1999) 1.35
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis (2007) 1.34
Diagnosis and treatment of malignant pleural effusion. Semin Oncol (1985) 1.33
Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res (1980) 1.31
Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res (2001) 1.31
Pleural effusion in breast cancer: a review of 105 cases. Cancer (1981) 1.24
Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration (1998) 1.21
Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer (1995) 1.13
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis (2006) 1.08
A structural view of integrin activation and signaling. Dev Cell (2003) 1.04
The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res (2004) 1.04
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol (2006) 1.03
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat (2004) 1.01
Anchorage-independent phosphorylation of p130(Cas) protects lung adenocarcinoma cells from anoikis. J Cell Biochem (2002) 0.93
Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol (1994) 0.86
Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol (1995) 0.84
Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol (2009) 0.83
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation (2002) 2.01
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene (2002) 1.96
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res (2004) 1.89
RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A (2004) 1.52
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res (2004) 1.44
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. Diagn Cytopathol (2003) 1.36
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem J (2002) 1.33
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol (2007) 1.23
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Laminin-induced signaling in tumor cells. Cancer Lett (2005) 1.21
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol (2006) 1.21
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol (2010) 1.20
Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res (2006) 1.17
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol (2005) 1.16
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis (2003) 1.13
MicroRNAs are associated with human embryo implantation defects. Hum Reprod (2011) 1.13
Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp Cell Res (2008) 1.12
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol (2008) 1.11
Retracted Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J Clin Oncol (2005) 1.09
Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol (2009) 1.08
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer (2013) 1.07
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol (2010) 1.07
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol (2010) 1.07
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis (2010) 1.04
The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol (2005) 1.03
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol (2006) 1.03
Do random estimations of vitamin D3 and parathyroid hormone reflect the 24-h profile in the critically ill? Intensive Care Med (2011) 1.02
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat (2004) 1.01
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol (2009) 1.00
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem (2004) 1.00
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (2006) 0.99
IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer Res (2012) 0.99
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol (2012) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer (2008) 0.98
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol (2004) 0.98
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer (2007) 0.98
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer (2013) 0.96
Genomic aberrations in borderline ovarian tumors. J Transl Med (2010) 0.95
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol (2009) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
The diagnostic role of claudins in serous effusions. Am J Clin Pathol (2007) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res (2003) 0.94
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol (2003) 0.94
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res (2007) 0.94
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.94
Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release (2006) 0.93
Disrupted gene pattern in patients with repeated in vitro fertilization (IVF) failure. Hum Reprod (2009) 0.93
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep (2012) 0.93
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol (2011) 0.92
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch (2006) 0.92
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol (2002) 0.92
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 0.91
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci (2011) 0.91
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol (2011) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol (2009) 0.90
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev (2003) 0.90
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol (2013) 0.90
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol (2007) 0.90
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res (2008) 0.89
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology. Diagn Cytopathol (2002) 0.89
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol (2004) 0.89